Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$1.63 CAD
Change Today +0.02 / 1.24%
Volume 43.9K
NTB On Other Exchanges
Symbol
Exchange
NASDAQ CM
Toronto
As of 4:00 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).

neptune tech & bioressources (NTB) Snapshot

Open
C$1.56
Previous Close
C$1.61
Day High
C$1.64
Day Low
C$1.56
52 Week High
06/19/14 - C$3.15
52 Week Low
10/14/14 - C$1.26
Market Cap
122.8M
Average Volume 10 Days
87.0K
EPS TTM
C$-0.37
Shares Outstanding
75.4M
EX-Date
07/24/08
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEPTUNE TECH & BIORESSOURCES (NTB)

Related News

No related news articles were found.

neptune tech & bioressources (NTB) Related Businessweek News

No Related Businessweek News Found

neptune tech & bioressources (NTB) Details

Neptune Technologies & Bioressources Inc., a biotechnology company, focuses on the research, development, and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. It produces marine-derived omega-3 polyunsaturated fatty acids, including Neptune Krill Oil (NKO), a dietary supplement for heart, joint, women, and brain health; ECOKRILL Oil, a generic krill oil; Rimfrost Oil, a generic krill oil; and Neptune Krill Aquatein, a protein ingredient used in the production of nursing feed for young animals, as well as new formulations derived from NKO, including NKO Beat, which targets heart and circulation health, NKO Flex, which targets bone and joint health, and NKO Focus, which targets brain and vision health. The company is also developing CaPre for the treatment of patients with severe hypertriglyceridemia and mild to moderate hypertriglyceridemia; and ONEMIA, a purified omega-3 phospholipids concentrate derived from krill oil with lower levels of phospholipids, eicosapentaenoic acid, and docosahexaenoic acid content, as well as researches, develops, and commercializes active pharmaceutical ingredients for the management of neurodevelopmental, memory, concentration, learning, and neurological disorders from prevention to treatment. Neptune Technologies & Bioressources Inc. sells its products in Canada, the United States, France, Belgium, Australia, and other countries. The company was founded in 1925 and is headquartered in Laval, Canada.

123 Employees
Last Reported Date: 05/27/15
Founded in 1925

neptune tech & bioressources (NTB) Top Compensated Officers

Head of Strategic Development
Total Annual Compensation: C$175.2K
Consulting Medical Science Liaison
Total Annual Compensation: C$196.0K
Compensation as of Fiscal Year 2014.

neptune tech & bioressources (NTB) Key Developments

Neptune Technologies & Bioressources, Inc. Announces Consolidated and Company Financial Results for the Fourth Quarter and Fiscal Year Ended February 28, 2015; Provides Consolidated Earnings Guidance for the First Quarter Ending May 31, 2015; Provides Consolidated Sales Guidance for the Second Quarter Ending August 31, 2015

Neptune Technologies & Bioressources, Inc. announced consolidated and company financial results for the fourth quarter and fiscal year ended February 28, 2015. The consolidated revenues totalled $4,021,000 for the three-month period ended February 28, 2015, up from $3,665,000 for the quarter ended February 28, 2014. Adjusted EBITDA was negative $9,964,000) for the quarter, versus negative $2,711,000 in the prior year. Net loss was $10,679,000 for the current quarter, versus a net loss of $1,327,000 in the prior year. The consolidated revenues were $15,070,000 for the fiscal year ended February 28, 2015, versus $19,496,000 for the year ended February 28, 2014. Adjusted EBITDA was negative $32,926,000 for the fiscal year, compared to negative $19,111,000 in the prior year. Net loss was $29,822,000 for the current year, versus a net loss of $22,237,000 in the prior year. The decrease in adjusted EBITDA and higher net loss is largely due to the same factors outlined for the quarterly results above. The company’s revenues were $3,843,000 for the three-month period ended February 28, 2015, compared to $3,465,000 for the three-month period ended February 28, 2014. Adjusted EBITDA was negative $7,405,000 for the quarter, versus negative $1,456,000 in the prior year. Net loss was $8,647,000 for the current quarter, compared to a net profit of $1,308,000 in the prior year. The company’s revenues totalled $14,799,000, for the twelve-month period ended February 28, 2015, compared to $18,995,000 for the corresponding year ended February 28, 2014. Adjusted EBITDA was negative $23,258,000 for the year, versus negative $12,858,000 in the prior year. Net loss totalled $28,946,000 for the fiscal year, compared to a net loss of $10,737,000 in the prior year. In line with Neptune's decision to slow production down to address product handling characteristics, consolidated sales for the first quarter ending May 31, 2015 are expected to come in at approximately $2.0 million, while the gross margin will remain under pressure. The company announced with the positive momentum the company is seeing at the plant and a robust sales pipeline that expects sales for the second quarter ending August 31, 2015 to be materially higher.

Neptune Technologies & Bioressources, Inc. Announces Board Changes

Neptune Technologies & Bioressources, Inc. announced its slate of director nominees for election at its next Annual and Special Meeting of shareholders to be held on July 14, 2015. The slate is comprised of four current directors, and three new director nominees. Katherine Crewe, Francois Roy and Leendert Staal will stand for election at the ASM as new nominees, while current directors Ronald Denis, M.D., Pierre Fitzgibbon, Jim Hamilton and John Moretz will stand for re-election. All three new independent director nominees are proven leaders with successful track records. A brief biography of each follows: Leendert Staal is a seasoned and accomplished senior executive with a strong track record of value creation. Dr. Staal has held numerous senior level positions within the DSM group, most recently as President and CEO of DSM Nutritional Products and previously as President and CEO of DSM Pharmaceuticals. Katherine Crewe is a strong and proactive leader with a consistent track record for identifying and maximizing manufacturing and business processes. She has spent 30 years in the medical device and pharmaceutical manufacturing space for companies with sales and distribution networks spanning the globe. During her career, she held several executive positions in various operations and quality management positions. Most recently, Mrs. Crewe was Managing Director, Canadian operations, at Mallinckrodt Pharmaceuticals and prior to this she was Vice President, Operations, at Cryocath Technologies. Mrs. Crewe is currently Chair of TEC-Canada, where she works with entrepreneurs, executives and business owners in understanding current challenges and opportunities and helps set objectives and goals, in order to meet new milestones. Francois Roy has extensive experience as a corporate director and executive in the private and public sectors. Most recently, Mr. Roy was Vice Principal (Administration and Finance) at McGill University, and also held the positions of Chief Financial Officer at Télémedia, and Executive Vice President and Chief Financial Officer at Quebecor Inc. In conjunction with these new additions to Neptune's board, Adrian Montgomery, Reed V. Tuckson, M.D., Harlan W. Waksal, M.D., and Jerald J. Wenker will be leaving Neptune's board, while seeking re-election on Acasti's board where their expertise will be focused on the development of Acasti's drug candidate, CaPre. Valier Boivin will be retiring from both boards.

Neptune Technologies & Bioressources, Inc., Q4 2015 Earnings Call, May 28, 2015

Neptune Technologies & Bioressources, Inc., Q4 2015 Earnings Call, May 28, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NTB:CN C$1.63 CAD +0.02

NTB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Apator SA 39.76 PLN -0.53
Badger Meter Inc $63.18 USD -1.34
Enzymotec Ltd $10.45 USD +0.15
Itron Inc $35.64 USD -0.25
Targeted Medical Pharma Inc $0.20 USD +0.10
View Industry Companies
 

Industry Analysis

NTB

Industry Average

Valuation NTB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.1x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEPTUNE TECH & BIORESSOURCES, please visit www.neptunebiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.